These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38093415)

  • 1. Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.
    Pelton SI; Mould-Quevedo JF; Nguyen VH
    Expert Rev Vaccines; 2024; 23(1):82-87. PubMed ID: 38093415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.
    Ruiz-Aragón J; Gani R; Márquez S; Alvarez P
    Hum Vaccin Immunother; 2020 Sep; 16(9):2238-2244. PubMed ID: 32040379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany.
    Cai R; Gerlier L; Eichner M; Schwehm M; Rajaram S; Mould-Quevedo J; Lamotte M
    J Med Econ; 2021; 24(1):490-501. PubMed ID: 33761803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of cell-based versus egg-based quadrivalent influenza vaccines in the pediatric population in Taiwan.
    Chi CY; Cheng MF; Ko K; Mould JF; Chen CJ; Huang YC; Lee PI
    J Med Virol; 2024 Jan; 96(1):e29279. PubMed ID: 38196182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina.
    Urueña A; Micone P; Magneres MC; McGovern I; Mould-Quevedo J; Sarmento TTR; Giglio N
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.
    Nguyen VH; Roy B
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach.
    Nguyen VH; Hilsky Y; Mould-Quevedo J
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population.
    Marbaix S; Dauby N; Mould-Quevedo J
    Expert Rev Vaccines; 2023; 22(1):608-619. PubMed ID: 37368472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
    Rumi F; Basile M; Cicchetti A; Alvarez FP; Azzi MV; Muzii B
    Front Public Health; 2023; 11():1200116. PubMed ID: 38026422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review.
    Mould-Quevedo JF; Pelton SI; Nguyen VH
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Vaccination of Older Adults with an MF59
    Jacob J; Biering-Sørensen T; Holger Ehlers L; Edwards CH; Mohn KG; Nilsson A; Hjelmgren J; Ma W; Sharma Y; Ciglia E; Mould-Quevedo J
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.